Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models.
|
31633500 |
2020 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
|
31667572 |
2020 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Notably, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric cancer, and has become the standard-of-care treatment for this group of patients.
|
31548601 |
2020 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibitors of CMIP could be used as potential adjuvant therapeutic drugs for HER2 positive gastric cancer.
|
31822364 |
2020 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the clinical significance of multi-targeting tyrosine kinase inhibitors (TKIs) in HER2-positive gastric cancer remains unclear.
|
31704817 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Gastric cancer (GC) has also been slow to benefit from biomarker discovery and development and the successful utilisation of targeted therapies, with the exception of trastuzumab in HER2 positive cancers.
|
30597479 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2-ECD (human epidermal growth factor receptor 2 - extracellular domain) is a prominent therapeutic target validated for treating HER2-positive breast and gastric cancer, but HER2-specific therapeutic options for treating advanced gastric cancer remain limited.
|
30365359 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings provide the basis for investigating the regulation of MAPK signaling pathways by HER2 and potential therapeutic targets for inhibiting metastasis and invasion in GC.
|
29734245 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Analysis of the genomic signature is not always feasible, and thus, we aimed to (i) develop and validate a practical immunohistochemistry (IHC)- and polymerase chain reaction (PCR)-based molecular classification of GC and (ii) to assess HER2 status according to this classification.
|
31371521 |
2019 |
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We aimed to evaluate whether HER2 expression in gastric cancer is affected by trastuzumab therapy.
|
30386954 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conclusion: Evaluation of HER2/neu status in gastric cancer patients
|
31350955 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2-positive.
|
30348707 |
2019 |
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Bioinformatics analyses conducted on a Caucasian-based cDNA microarray databank showed Ar to be positively associated with GCa prognosis for multiple clinical modalities, including surgery, 5-Fluorouracil (5-FU) for adjuvant chemotherapy, or HER2 positivity.
|
31557413 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
After phase III clinical trials, trastuzumab, anti-Erb-B2 receptor tyrosine kinase 2 (commonly known as ERBB2) and ramucirumab, anti-vascular endothelial growth factor receptor 2 (commonly known as VEGFR2) monoclonal antibodies, were approved and introduced into first- and second-line therapies for patients with advanced/metastatic GC.
|
31662821 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
PD-L1 membrane expression on tumour cells (TC) and infiltrating immune cells (IC), CD3 + T-lymphocytes, CD8+ cytotoxic T-cells, ATM and HER2 were assessed by immunohistochemistry (IHC) in the ACRG (Asian Cancer Research Group) GC cohort (N = 380).
|
30729066 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany.
|
30826877 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, d16HER2 may be considered as a "flag" of HER2 dependence in GC and can be clinically investigated as a marker of trastuzumab susceptibility in several other HER2-driven cancers, including CRC.
|
30837627 |
2019 |
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of circular RNA circ-ERBB2 predicts unfavorable prognosis and facilitates the progression of gastric cancer via miR-503/CACUL1 and miR-637/MMP-19 signaling.
|
30853181 |
2019 |
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
|
30442682 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined.
|
31126258 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The diagnosis of HER2 positive cancer types such as breast- and gastric cancer is usually based on immunohistochemical HER2 staining of tumour tissue.
|
31455202 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Patients with HER2-positive GC previously treated with one line of chemotherapy received oral poziotinib (8 mg or 12 mg) once daily for 14 days, followed by 7 days off.
|
30945121 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
With the exception of gastric cancer, there are currently no defined guidelines for HER2 testing in other digestive tumors.
|
31170116 |
2019 |
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The rate of human epidermal growth factor receptor 2 upregulation in patients with GC was 13.33% and it was associated with nerve invasion (χ<sup>2</sup>=4.005, P=0.045) and TNM stages III/IV (χ<sup>2</sup>=5.600, P=0.018).
|
31620201 |
2019 |
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
|
30269082 |
2019 |